Tech Company Financing Transactions
Ollin Biosciences Funding Round
Ollin Biosciences, operating out of Austin, secured $330 million from Arch Venture Partners, TCGX and Andreessen Horowitz.
Transaction Overview
Company Name
Announced On
6/24/2026
Transaction Type
Venture Equity
Amount
$330,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support global Phase 3 trials of OLN324, a potential VEGF/Ang2 antibody addressing causes of vision loss in the $15 billion retina market
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1250 S Capital of Texas Hwy, Bldg 3 400
Austin, TX 78746
USA
Austin, TX 78746
USA
Phone
Undisclosed
Website
Email Address
Overview
Ollin Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for severe, vision-threatening ophthalmic diseases. Established in 2023 and headquartered in Austin, Texas, the company targets complex, multifactorial eye conditions by building upon clinically validated biologies to maximize efficacy and improve patient outcomes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jason Ehrlich
Browse more venture capital transactions:
Prev: 6/24/2026: Anodyne Nanotech venture capital transaction
Next: 6/24/2026: Hang Ten Systems venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs